Essential Tremor Dosing With T-Type Calcium Channel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for essential tremor, such as propranolol and primidone, are characterized by serious side effects and are not effective for all patients, highlighting the need for alternative methods that improve tolerability and efficacy in treating this common movement disorder.
Innovation Solution
Administration of a compound of formula (I) or its pharmaceutically acceptable salt, such as ulixacaltamide, at doses ranging from 60 mg to 100 mg once daily, optionally through a titration period, to reduce the Essential Tremor Rating Assessment Scale (TETRAS) performance score in subjects with essential tremor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current treatments for essential tremor (propranolol and primidone) are used, then tremor symptoms are suppressed, but serious side effects occur and tolerability is poor
Solution Approach 1:
The patent applies parameter changes by developing a novel T-type calcium channel blocker with modified chemical structure (Formula I) and optimized dosing parameters (60-100 mg once daily). This new compound achieves tremor suppression while maintaining a different safety profile compared to existing drugs like propranolol and primidone, thereby reducing serious side effects while preserving therapeutic efficacy.
2Object-affected harmful factors
If current treatments for essential tremor are used, then some tremor symptoms are suppressed, but effectiveness is insufficient for all patients
Solution Approach 1:
The patent employs parameter changes by introducing a new chemical compound with optimized pharmacological properties. The compound of Formula I demonstrates improved effectiveness across diverse patient populations by targeting T-type calcium channels with enhanced selectivity and potency, thereby increasing treatment reliability compared to existing therapies that fail in some patients.
3Object-affected harmful factors
If higher doses of T-type calcium channel blockers are administered, then tremor suppression is improved, but adverse effects may increase
Solution Approach 1:
The patent applies parameter changes through optimized dosing regimens (60-100 mg once daily) combined with a novel compound structure. This approach achieves effective tremor suppression while maintaining adverse effects at minimal levels, representing an optimized balance between therapeutic benefit and safety compared to higher dosing strategies.
Solution Approach 2:
The patent uses the novel compound of Formula I as an intermediary substance that mediates between the need for effective tremor suppression and the concern for adverse effects. This intermediate compound provides a middle ground solution that achieves therapeutic goals without the extreme dosing required by other approaches, thereby minimizing harmful side effects.
Data Source
AI summary
The present disclosure relates to methods of treating essential tremor that comprise administering to a subject in need thereof compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject once daily at a dose of about 60 mg to about 100 mg; such that The Essential Tremor Rating Assessment Scale (TETRAS) performance score of said subject is decreased following administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof, as compared to the TETRAS performance score of said subject prior to the administration of the compound of formula (I), or a pharmaceutically acceptable salt thereof.